BSX - Athenex Mixed Results Boston Scientific Approval And Other News: The Good Bad And Ugly Of Biopharma
Athenex (ATNX) stock tumbled as it released pivotal trial results for its lead drug candidate, an experimental combination treatment for metastatic breast cancer. The Phase 3 trial tested oral paclitaxel along with encequidar, an inhibitor that aims to make chemotherapies more effective. The data showed that the combination offered a stronger response rate and higher median overall survival as compared to infused paclitaxel.
Despite these results, the stock responded negatively but later recovered as the market fully digested the outcome of the trial. The study showed that oral paclitaxel shrank tumors for 35.8%